Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,171,533
  • Shares Outstanding, K 92,292
  • Annual Sales, $ 788,090 K
  • Annual Income, $ 37,010 K
  • 60-Month Beta 1.42
  • Price/Sales 10.83
  • Price/Cash Flow 135.68
  • Price/Book 13.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.57
  • Number of Estimates 11
  • High Estimate 0.95
  • Low Estimate 0.05
  • Prior Year -1.12
  • Growth Rate Est. (year over year) +150.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.14 +26.96%
on 03/18/20
98.37 -6.89%
on 03/04/20
-3.11 (-3.28%)
since 02/28/20
3-Month
72.14 +26.96%
on 03/18/20
115.24 -20.52%
on 01/10/20
-16.85 (-15.54%)
since 12/27/19
52-Week
71.85 +27.47%
on 04/30/19
119.65 -23.45%
on 12/04/19
+3.49 (+3.96%)
since 03/29/19

Most Recent Stories

More News
COLL or NBIX: Which Is the Better Value Stock Right Now?

COLL vs. NBIX: Which Stock Is the Better Value Option?

COLL : 16.92 (+3.30%)
NBIX : 91.59 (+3.44%)
COLL or NBIX: Which Is the Better Value Stock Right Now?

COLL vs. NBIX: Which Stock Is the Better Value Option?

COLL : 16.92 (+3.30%)
NBIX : 91.59 (+3.44%)
Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 40th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday, Mar. 3, 2020, in Boston. Kevin Gorman, Chief Executive Officer,...

NBIX : 91.59 (+3.44%)
Watch for Neurocrine Biosc to Potentially Pullback After Gaining 1.01% Yesterday

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $100.40 to a high of $106.00. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high...

NBIX : 91.59 (+3.44%)
Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -57.32% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

NBIX : 91.59 (+3.44%)
Neurocrine: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Tuesday reported fourth-quarter profit of $34 million.

NBIX : 91.59 (+3.44%)
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2019 and provided full-year 2020 financial expense guidance.

NBIX : 91.59 (+3.44%)
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx,...

NBIX : 91.59 (+3.44%)
The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group

The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group

SAVE : 12.42 (-16.02%)
NS : 7.19 (unch)
WAT : 188.14 (+1.50%)
NBIX : 91.59 (+3.44%)
RMR : 28.24 (-2.62%)
5 Top Stocks Set to Beat Earnings Estimates Next Week

Although, expectations for fourth-quarter 2019 earnings are negative at present, results so far are far better than initially anticipated.

SAVE : 12.42 (-16.02%)
NS : 7.19 (unch)
WAT : 188.14 (+1.50%)
NBIX : 91.59 (+3.44%)
RMR : 28.24 (-2.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade NBIX with:

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

2nd Resistance Point 94.22
1st Resistance Point 92.90
Last Price 91.59
1st Support Level 89.81
2nd Support Level 88.04

See More

52-Week High 119.65
Fibonacci 61.8% 101.39
Fibonacci 50% 95.75
Last Price 91.59
Fibonacci 38.2% 90.11
52-Week Low 71.85

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar